1-3 of 3
Lisa R. Rodriguez
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas

Maryam Sarraf Yazdy, Yvette L. Kasamon, Wenjuan Gu, Lisa R. Rodriguez, Susan Jin, Vishal Bhatnagar, Nicholas C. Richardson, Marc R. Theoret, Richard Pazdur, Nicole J. Gormley
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (24): 5521–5526.
https://doi.org/10.1158/1078-0432.CCR-24-1729
Published: 16 December 2024
View articletitled, FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas
Open the PDF for FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas in another window
Journal Articles

Improving Collection and Analysis of Overall Survival Data

Lisa R. Rodriguez, Nicole J. Gormley, Ruixiao Lu, Anup K. Amatya, George D. Demetri, Keith T. Flaherty, Ruben A. Mesa, Richard Pazdur, Mikkael A. Sekeres, Minghua Shan, Steven Snapinn, Marc R. Theoret, Rukiya Umoja, Jonathon Vallejo, Nicholas J.H. Warren, Qing Xu, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 3974–3982.
https://doi.org/10.1158/1078-0432.CCR-24-0919
Published: 13 September 2024
View articletitled, Improving Collection and Analysis of Overall Survival Data
Open the PDF for Improving Collection and Analysis of Overall Survival Data in another window
Journal Articles

FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Deepti Telaraja, Yvette L. Kasamon, Justin S. Collazo, Ruby Leong, Kun Wang, Ping Li, Elyes Dahmane, Yuching Yang, Justin Earp, Manuela Grimstein, Lisa R. Rodriguez, Marc R. Theoret, Nicole J. Gormley
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 17–22.
https://doi.org/10.1158/1078-0432.CCR-23-1272
Published: 05 January 2024
View articletitled, FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Open the PDF for FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma in another window